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Abstract
Background: BRAF is a member of RAF family of serine/threonine kinases and mediates cellular
responses to growth signals through the RAS-RAF-MAP kinase pathway. Activating mutations in
BRAF have recently been found in about 10% of colorectal cancers, with the vast majority being a
V600E hotspot mutation. The aim of the present study was to evaluate the clinical, pathological and
molecular phenotype of colorectal tumors with BRAF mutations.
Results: Mutations in BRAF were identified in 8% (23/275) of colorectal cancers. They were 5–10-
fold more frequent in tumors with infiltrating lymphocytes, location in the proximal colon, poor
histological grade and mucinous appearance (P < 0.002 for each). Tumors with BRAF mutation were
also 10-fold more likely to show microsatellite instability and frequent DNA methylation (P <
0.0001) compared to tumors without this mutation. The characteristic morphological features of
tumors with BRAF  mutation (infiltrating lymphocytes, poor grade, mucinous) remained after
stratification according to microsatellite instability and methylator phenotypes. Mutations in BRAF
were mutually exclusive with mutations in KRAS but showed no clear association with the presence
of TP53 mutation.
Conclusion: BRAF mutation identifies a colorectal cancer subgroup with distinctive phenotypic
properties independent of microsatellite instability status and thus could be a valuable marker for
studies into the clinical properties of these tumors.
Background
BRAF is a member of the RAF family of kinases that acts
upstream of the MEK1/2 kinases in response to RAS sig-
nals. Activating mutations in BRAF have been reported in
5–15% of colorectal carcinomas (CRC), with by far the
most common mutation being a 1796T to A transversion
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leading to a V600E substitution [1-3]. The BRAF V600E
hotspot mutation is strongly associated with the microsat-
ellite instability (MSI+) phenotype but is mutually exclu-
sive with KRAS  mutations [4-7]. Interestingly, BRAF
mutations are found only in MSI+ sporadic tumors that
result from aberrant MLH1 promoter methylation and do
not occur in MSI+ tumors from hereditary non-polyposis
colorectal cancer (HNPCC) patients [5,8-10], thus provid-
ing a convenient discriminator between sporadic and
familial cases. The majority of MSI+ sporadic tumors
belong to a larger CRC group referred to as the CpG island
methylator phenotype (CIMP+) that is characterised by
widespread hypermethylation of CpG islands located
with gene promoter regions [11]. Both MSI+ and CIMP+
tumors are thought to arise from large hyperplastic polyps
and serrated adenomas [12,13] and recent work has dem-
onstrated a high frequency of BRAF mutations in these
lesions [7,14,15].
Although the positive association with MSI+ and inverse
association with KRAS  mutation have been well docu-
mented, little is known about the other properties of
tumors with BRAF mutation. In the present study we ana-
lysed for BRAF V600E mutations in a consecutive series of
275 CRCs that were well characterised for the major path-
ological and molecular features of this disease. Our results
demonstrate that oncogenic BRAF mutation occurs prefer-
entially within a subgroup of CRCs that have distinctive
features. It could therefore be used as a convenient marker
for the further characterisation of these tumors, particu-
larly in relation to their prognosis and response to adju-
vant chemotherapy.
Results
Figure 1A shows representative Fluorescent-SSCP results
for the screening of BRAF mutations in this CRC series,
while Figure 1B shows DNA sequencing confirmation of
the 1799T to A transversion resulting in the V600E muta-
tion. The overall frequency of BRAF mutation was 8.4%
(23/275), comparing favourably with frequencies of 9–
11% reported for other large studies of this tumor type
[6,16,17]. The mean age of patients with and without
BRAF mutation was identical (Table 1). Strong associa-
tions were observed between BRAF mutation and tumor
origin in the proximal side of the large bowel, poor histo-
logical grade, mucinous appearance and the presence of
infiltrating lymphocytes. Higher frequencies of BRAF
mutation were also observed in females and in node neg-
ative tumors but these did not reach significance.
BRAF mutations showed no association with TP53 muta-
tions and were mutually exclusive with the presence of
KRAS mutations (Table 2). In contrast, BRAF mutations
were approximately 10-fold more frequent in MSI+ and
CIMP+ tumors compared to tumors without these pheno-
types. A strong association was also seen with methylation
of the MLH1 gene promoter and in particular with meth-
ylation of its proximal region. We have previously exam-
ined the methylation status of 7 different CpG islands in
this CRC series [18]. The mean number of these methyl-
ated sites was 3-fold higher in tumors with BRAF muta-
tion compared to those without (2.6 ± 1.7 vs 0.8 ± 1.0; P
< 0.001). Multivariate analysis revealed that MSI+ was the
only significant independent predictor of BRAF mutation
(RR = 6.3, 95%CI [1.2–32.3]; P = 0.028) in a model that
included CIMP+, tumor site, histological grade, presence
of infiltrating lymphocytes and mucinous appearance.
We next examined whether the characteristic features of
tumors with BRAF mutation were still apparent following
stratification into MSI and CIMP phenotypes. Although
the statistical power of this subgroup analysis was limited,
the morphological features of infiltrating lymphocytes,
poor histological grade and mucinous appearance were
clearly associated with BRAF mutation regardless of tumor
MSI status (Table 3). Similarly, these features were each
more common in tumors with BRAF mutation in both the
CIMP- and CIMP+ subgroups (Table 4). Similar to previ-
ous observations in a separate CRC cohort [20], the fre-
quency of KRAS mutation was lower in MSI+ compared to
MSI- tumors (P = 0.034; Table 3), while the frequency of
TP53  mutation was also considerably lower in MSI+
(A) Representative F-SSCP gel used to detect BRAF mutation- sin colorectal cancer Figure 1
(A) Representative F-SSCP gel used to detect BRAF mutation-
sin colorectal cancer. WT, wild-type; M, mutation. (B) DNA 
sequencing gel resultconfirms the presence of a 1799T to A 
mutation giving rise to the V600E mutation.
(A) BRAF V600E mutation screening using F-SSCP
WT    M     M      M WT   WT    WT    M     WT
(B) DNA sequence showing BRAF 1799T to A mutation
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tumors with wildtype BRAF  than in MSI- tumors with
wildtype BRAF (P = 0.014).
Discussion
The BRAF V600E mutation has already been proposed as
a convenient marker to discriminate between MSI+
tumors that are sporadic or HNPCC in origin [5,8-10].
This is a very important issue for population-based screen-
ing programs that aim to identify CRC associated with the
HNPCC syndrome. Compared to the analysis of MLH1
promoter methylation, mutation at the BRAF  V600E
hotspot is relatively simple to detect using DNA sequenc-
ing, RFLP or the SSCP method used in the present work
(Figure 1).
Similar to other studies [4,5,10,16,17] we observed BRAF
mutation frequencies of 4% in MSI- tumors and 39% in
MSI+ tumors (Table 1). The highest frequencies were seen
in tumors showing methylation of the MLH1 promoter
proximal region (46%) and in tumors with infiltrating
lymphocytes (48%). BRAF mutation frequencies of up to
70–80% have been reported in sporadic MSI+, CIMP+
and MLH1-methylated CRC and polyps [7,8,15,16]. For
reasons that are still unclear, BRAF mutations are approx-
imately 5–10-fold more frequent in tumors that have
characteristic features of sporadic MSI+ (ie. MLH1 methyl-
ated) and CIMP+ phenotypes. These include proximal
colon location, poor differentiation, mucinous histology
and infiltrating lymphocytes [13,19,20]. Interestingly
however, in the present study BRAF  mutations never
occurred in association with KRAS mutation, were present
in only 3% of CIMP- tumors and showed no association
with TP53 mutation (Table 2). The observation that BRAF
mutations occur only very rarely in HNPCC-related MSI+
CRC demonstrates that defective DNA mismatch repair is
not involved in causing this genetic alteration.
In order to determine whether the characteristic clinico-
pathological features of tumors with BRAF mutation were
due to their close association with MSI+ and CIMP+, we
stratified tumours according to these phenotypes. Despite
having only 9 MSI-/BRAF  mutant and 5 CIMP-/BRAF
mutant tumors, the results showed that associations
between BRAF mutation and the morphological proper-
ties of tumor-infiltrating infiltrating lymphocytes, poor
histological grade and mucinous phenotype were retained
(Tables 3 and 4).
The frequencies of BRAF mutation observed in MSI- (4%)
and MSI+ (39%) tumors in the present study compare
Table 1: Associations between BRAF mutation and clinicopathological features of colorectal cancer.
Feature (n) a BRAF wild-type (%) BRAF mutation (%) P
Total (275) 252 (92) 23 (8)
Age (yrs) 68.4 ± 13.0 68.4 ± 20.7 NS
Gender
Men (132) 124 (94) 8 (6)
Women (100) 87 (87) 13 (13) 0.068
Infiltrating lymphocytes
Negative (199) 190 (95) 9 (5)
Positive (21) 11 (52) 10 (48) <0.0001
Nodal involvement
Negative (128) 115 (90) 13 (10)
Positive (70) 66 (94) 4 (6) NS
Tumor site
Proximal (93) 79 (85) 14 (15)
Distal (126) 122 (97) 4 (3) 0.0015
Histological grade
Well/moderate (140) 133 (95) 7 (5)
Poor (29) 22 (76) 7 (24) 0.0006
Mucinous
Negative (159) 150 (94) 9 (6)
Positive (27) 20 (74) 7 (26) 0.0005
a Data was unavailable for gender in 43 cases, infiltrating lymphocytes in 55 cases, nodal involvement in 77 cases, tumor site in 56 cases, grade in 106 
cases and mucinous appearance in 89 cases.Molecular Cancer 2006, 5:2 http://www.molecular-cancer.com/content/5/1/2
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favourably (5% and 52%, respectively) to those reported
recently in another large, population-based study [17].
Although BRAF  mutations are much more frequent in
MSI+ tumors, the comparative rarity of this phenotype
means that a considerable proportion occur in MSI-
tumors. In the present study, 43% of all BRAF mutations
occurred in MSI- tumors compared to 48% in the study by
Samowitz et al [17]. BRAF mutations were reported to
show prognostic significance in MSI- but not in MSI+ CRC
[17]. The lack of follow-up information on CRC patients
in the current study and the small number of BRAF muta-
tions (n = 21) meant that we were unable to evaluate the
prognostic significance of BRAF  mutation according to
MSI status.
Table 2: Associations between BRAF mutation and molecular features of colorectal cancer.
Feature (n) a BRAF wild-type (%) BRAF mutation (%) P
Total (275) 252 (92) 23 (8)
MSI
negative (204) 195 (96) 9 (4)
positive (31) 19 (61) 12 (39) <0.0001
Methylation status
CIMP- (150) 145 (97) 5 (3)
CIMP+ (42) 31 (74) 11 (26) <0.0001
MLH1 distal region
Negative (168) 159 (95) 9 (5)
Positive (24) 17 (71) 7 (29) <0.0001
MLH1 proximal region
Negative (179) 169 (94) 10 (6)
Positive (13) 7 (54) 6 (46) <0.0001
KRAS
Wild-type (156) 134 (86) 22 (14)
Mutant (93) 93 (100) 0 (0) <0.0001
TP53
Wild-type (183) 166 (91) 17 (9)
Mutant (66) 62 (94) 4 (6) NS
a Data was unavailable for MSI status in 40 cases, methylation status in 83 cases, KRAS mutation in 26 cases and TP53 mutation in 26 cases
Table 3: Clinicopathological and molecular features of BRAF mutant colorectal cancers stratified according to microsatellite instability 
status.
MSI- MSI+
Feature BRAF WT 
(n = 192) (%)
BRAF M 
(n = 9) (%)
PB R A F   WT 
(n = 19) (%)
BRAF M 
(n = 12) (%)
P
Age (years) 68.5 ± 12.6 58.2 ± 26.5 NS 67.5 ± 16.8 76.1 ± 10.9 NS
Females 39 44 NS 63 75 NS
TILS + a 3 44 0.0004 28 60 0.08
Node negative 62 62 NS 81 89 NS
Proximal site 36 67 0.05 72 89 NS
Poor grade 15 40 0.12 25 56 0.11
Mucinous 12 53 0.05 6 44 0.04
CIMP+ 15 50 0.03 40 88 0.03
Dist. MLH1 methylated 7 12 NS 40 75 0.10
Prox. MLH1 methylated 1 0 NS 33 75 0.06
KRAS mutant 43 0 0.008 21 0 0.12
TP53 mutant 29 11 NS 5 18 NS
aTumor-infiltrating lymphocytesMolecular Cancer 2006, 5:2 http://www.molecular-cancer.com/content/5/1/2
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Conclusion
Findings from the present study and from previous work
indicate that BRAF mutation is likely to be a convenient
marker for the identification of a subset of CRCs with dis-
tinctive clinical, pathological and molecular features and
which may originate in hyperplastic polyps and serrated
adenomas [7,14,15]. In view of the strong associations
between BRAF mutation and specific pathological (site,
grade, mucinous, infiltrating lymphocytes) and molecular
(methylated MSI+, CIMP+, wildtype KRAS) features, it
will be interesting in future studies to determine the pre-
dictive significance of this marker for response to adjuvant
therapies in CRC.
Methods
The 275 colorectal tumors investigated in this study were
obtained from the Colorectal Unit of the Royal Adelaide
Hospital. These were snap frozen in liquid nitrogen
within 20–40 min after resection and stored at -70°C
prior to extraction of DNA. Clinical data available for this
series included patient age, sex and family history of CRC.
Only one case was confirmed as HNPCC-related. Patho-
logical data included nodal involvement, tumor site, his-
tological grade, mucinous appearance and the presence of
infiltrating lymphocytes. Evaluation of MSI+ [21], CIMP+
[18], KRAS mutation [22] and TP53 mutation [23] were
performed as described previously by our group. Muta-
tions in exon 15 of BRAF including the V600E hotspot
were detected using the PCR primer sequences reported
earlier [1], the F-SSCP method [22,23] and confirmed by
direct sequencing.
Statistical analyses were performed using SPSS Version
12.0 (Chicago, Illinois, USA). Associations between BRAF
mutation and clinical, pathological or molecular features
were evaluated using Fisher's exact or Pearson's chi-
squared tests as appropriate. Multivariate analysis was
performed using binary logistic regression with BRAF
mutation as the dependent variable.
List of abbreviations
Colorectal carcinoma, CRC; microsatellite instability,
MSI+; hereditary non-polyposis colorectal cancer,
HNPCC; CpG island methylator phenotype, CIMP+; fluo-
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SSCP; tumor-infiltrating lymphocytes, TILs.
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